Introduction Macrophages acquire strikingly different properties that enable them to play key roles during the initiation, propagation and resolution of inflammation. Classically-activated macrophages produce pro-inflammatory mediators that help to combat invading pathogens and respond to tissue damage in the host, whereas regulatory macrophages produce high levels of anti-inflammatory molecules, such as interleukin (IL)-10, and low levels of pro-inflammatory cytokines, like IL-12, and are important for the resolution of inflammatory responses. A central problem in this area is to understand how the formation of regulatory macrophages can be promoted at sites of inflammation to prevent and/or alleviate chronic inflammatory and autoimmune diseases. Methods Bone-marrow derived macrophages were treated with protein kinase inhibitors prior to stimulation with Toll-like receptor (TLR) agonists. mRNA synthesis was measured by qPCR and cytokine secretion was measured using the BIOPLEX system. To identify the relevant substrate, the effects of the protein kinase inhibitors on the phosphoproteome were measured by LC-MS/MS. Subsequently, the repertoire of phosphorylation sites were mapped and their effects on protein function were analyzed using luciferase assays. Finally, the targets of the protein kinase inhibitors were validated in mouse knock-outs. Results We have discovered a novel mechanism that restricts the formation of regulatory macrophages. This has led us to identify the first small-molecule inhibitors of protein kinases capable of inducing all the hallmarks of regulatory macrophages, including the production of high levels of IL-10 and IL-1ra. The molecular mechanism underlying the effects of these compounds will be presented. Conclusion The remarkable effects of these protein kinase inhibitors on macrophage function suggest a novel approach for the development of anti-inflammatory drugs.
Read full abstract